CD4 and non-small cell lung carcinoma: In addition, our ROC working curves demonstrated that the AUC areas of baseline CD4+ T cells, NK cells, and Tregs predicted the efficacy of immunotherapy in NSCLC patients as 0.690, 0.634, and 0.722, respectively (Fig. 2).